FARO Technologies (FARO): Impressive efficiency turnaround despite revenue decline drives the stock up! FARO Technologies, a leading provider of 3D digital reality solutions, has made impressive progress in profitability despite slightly declining revenues in the fiscal year 2024. Notably, gross margins significantly improved, rising to 56.7% in...
The Best Relative Strength Stocks
The Relative Strength Indicator compares a stock with all others, with the last quarter being weighted the most.
| Rank | Stock | Price | Perf. 20D | Dist. SMA200 | Rel. Strength |
|---|---|---|---|---|---|
| WKN | Symbol | Perf. 250D | ||||
| 1 | Red Cat Holdings | 8.51 $ | -1.40 % | 84.14 % | 100 |
| A2PPXB | RCAT | 1,088.37 % | ||||
| 2 | Rigetti Computing | 11.51 $ | -14.55 % | 198.84 % | 100 |
| A3DE3J | RGTI | 623.90 % | ||||
| 3 | Bluebird Bio | 0.38 $ | - % | - % | 100 |
| A1W025 | BLUE | - % | ||||
| 4 | Innodata | 70.12 $ | 74.33 % | 177.16 % | 100 |
| 907651 | INOD | 893.22 % | ||||
| 5 | Eyenovia | 0.04 $ | - % | - % | 100 |
| EYEN | - % | ||||
| 6 | Hims & Hers Health | 55.76 $ | 80.51 % | 135.46 % | 100 |
| A2QMYY | HIMS | 490.06 % | ||||
| 7 | Chimerix | 5.25 $ | 32.70 % | 225.73 % | 100 |
| A1T65B | CMRX | 345.34 % | ||||
| 8 | Kingstone Companies | 17.24 $ | 12.02 % | 69.11 % | 100 |
| A0X89S | KINS | 447.30 % | ||||
| 9 | Eos Energy Enterprises | 4.71 $ | -23.91 % | 69.06 % | 100 |
| A2QD94 | EOSE | 423.62 % | ||||
| 10 | Clover Health Investments | 4.44 $ | -7.93 % | 58.04 % | 100 |
| A2QJXX | CLOV | 391.44 % | ||||
Subscribe now to see the full ranking
Already a subscriber? Login
Sample Issue
$
0
one issue
Bestseller
Trial Subscription
$
33
1 month
• Production of GLP-1 Analogues Ends: With the end of the Wegovy supply shortage, Hims & Hers must cease production by May 2025 – a heavy blow for the revenue-rich weight loss segment. • Anticipation Ahead of Q4 Numbers: Despite a share price drop of 25%, investors hope for strong quarterly results and details on the future strategy in...
After the release of the results for the 4th quarter and the entire year of 2024, shares of Hims & Hers Health Inc. fell by up to 20% in after-hours trading. Although the company presented impressive financial figures, the announcement to cease the sale of commercial GLP-1 drugs containing the active ingredient semaglutide caused uncertainty in...
• Production of GLP-1 mimetics ends: With the end of the Wegovy supply shortage, Hims & Hers must halt production by May 2025 – a heavy blow for its lucrative weight loss segment. • Tension ahead of Q4 results: Despite a 25% drop in stock price, investors are hopeful for strong quarterly results and details on the future strategy...
Business Driver: Hims & Hers (HIMS) is one of the leading US providers in the field of telemedicine. Since the platform also offers consultations and medications for sensitive conditions such as gender-related diseases for both men and women, as well as mental health issues, the customer base has been significantly increasing and now includes more...